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INTRODUCTION
The majority of patients diagnosed with lung cancer have
advanced disease, and only 15-20% are candidate for surgery
at the time of diagnosis (1). Metastases to the lung are com-
mon, and endobronchial metastatic tumor deposits mimick-
ing a primary bronchogenic carcinoma are well documented
(2). Local progression of lung malignancy that affects the air-
way, either endobronchially or by extrinsic compression, oc-
curs in almost 80% of patients, and many become sympto-
matic with dyspnea or post-obstructive pneumonia. As a re-
sult, many patients with inoperable lung malignancy require
palliative treatment (3). Bronchoscopic treatment of airway
malignancies is usually considered in patients with surgically
unresectable lesions, and is aimed at relieving obstructive sym-
ptoms rather than curing the neoplasm. 
The standard method of palliating symptoms of patients
with inoperable non-small cell carcinoma is external beam
radiotherapy (EBRT), which has limitation of slowness in
response and morbidity proportional to radiation dose. There
is therefore a need for alternative treatment modalities. The
endobronchial therapies including the techniques of laser
therapy (LT), brachytherapy (BT), prosthetic stents, cryother-
apy, photodynamic therapy, radiofrequency, and electrocautery
have brought important improvements in the control of lung
tumors. LT for malignant tumors is purely palliative and
should be performed in unresectable case (4). The laser pro-
vides immediate and often dramatic relief of symptom in pa-
tients with localized obstruction of the large airways caused
by endobronchial tumor. However, it is not effective in man-
aging patients with extrinsically compressed airways and the
duration of symptomatic relief may be very brief (5). BT is
used to deliver radiation therapy from within the airway lu-
men to treat malignant tumors that obstruct the airways. In
general, high dose rate brachytherapy (HDR-BT) is a good
palliative treatment, and well tolerated with few reported
complications (6, 7). 
The use of HDR-BT as a component of therapy for locally
advanced non-small cell lung cancer (NSCLC) has been de-
scribed, but its benefits has not been proven; no significant
benefit in survival has yet been achieved, except in selected
groups (8, 9), and the survival benefit has not been compared
to that of external beam radiotherapy alone (10, 11). The com-
bination of endobronchial LT with other palliative therapies
Tae Won Jang, Glen Blackman*, 
Jeremy J George
�
Department of Internal medicine, Kosin University
College of Medicine, Busan, Korea; Department of
Radiotherapy*, Thoracic Medicine
� , University 
College London Hospitals. London, U.K.
Address for correspondence
Tae Won Jang, M.D.
Department of Internal Medicine, Kosin University
College of Medicine, 34 Amnam-dong, Suh-gu,
Busan 602-702, Korea
Tel : +82.51-990-6637, Fax : +82.51-248-5686
E-mail : jangtw@ns.kosinmed.or.kr
*This work was supported by research fund of Kosin
University College of Medicine, Busan, Korea. 
341
J Korean Med Sci 2002; 17: 341-7
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Survival Benefits of Lung Cancer Patients Undergoing Laser 
and Brachytherapy
We aimed to compare the duration of survival among subjects receiving brachyther-
apy (BT) in combination with Nd:YAG laser therapy (LT), and those receiving LT
or BT alone. The medical records of subjects who received endobronchial treatment
for unresectable tracheobronchial malignancies between January 1997 and Decem-
ber 1999 in a single center were reviewed retrospectively. A total of 80 patients
were evaluated. The overall symptomatic response rate after treatment was 86.5%.
Median survival durations for the LT, BT, and combined therapy (CT) group were
111, 115, and 264 days, respectively. The survival duration was significantly longer
in the CT group than in the BT group (p=0.0078), but the difference was not sta-
tistically significant between the CT and the LT group. The bronchoscopic finding
of endobronchial polypoid lesion was associated with a longer survival time than
extraluminal with compression type (p=0.0023) by univariate analysis. Other factors
associated with the better prognosis included hemoglobin ≥12.5 g/dL, serum albu-
min level ≥37 g/L, and BT dose ≥15 Gy at 1 cm distance. Of these factors, spe-
cific bronchoscopic findings, serum albumin level, CT modality, and dose of BT re-
tained statistical significance in multivariate analysis. In conclusion, combined LT
and BT is associated with increased patient survival compared with BT alone. Com-
bined therapy may improve survival time in selected patients with endobronchial
malignancies. 
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is possible and can extend the duration of palliation. The com-
bined therapy (CT) with LT and BT may lead to an increased
survival in patients, compared to those undergoing a single
treatment modality. However, there are few published data
showing the survival benefits of the CT (12). This study was
undertaken to examine the length of the survival of patients
who had undergone CT compared with LT or BT alone in a
single center utilizing high-dose 192Iridium (Ir) in the treat-
ment of malignant lung cancers through a retrospective anal-
ysis. 
MATERIALS AND METHODS
The medical records of patients who had undergone LT or
BT from January 1997 to December 1999 at the Middlesex
Hospital, University College London Hospitals were review-
ed. We recorded patients’ characteristics, prognostic factors
including stage, pathologic cell type, bronchoscopic findings,
treatment modality, technical details of the BT, symptomat-
ic response, survival time, and complications. Data on death
were obtained from, mainly, data of Thames Cancer Registry,
notification of death forms in medical records, and reply let-
ters from General Practitioners.
The patients were divided into three groups according to
whether they had been treated with LT, BT, and CT. Survival
was measured from the date of the first episode of LT or BT.
We classified bronchoscopic findings using a classification
system modified by Bucheri et al. (13). Endobronchial nodular
and infiltrative type (EN) was defined as an endobronchial
mass presenting as either a predominantly intraluminal nodular
growing mass or mucosal infiltration. Endobronchial poly-
poid (EP) type was defined as an intraluminal lobulated fleshy
growth. Extraluminal with compression (EC) referred to a
tumor with an irregular area of mucosal surface with infiltra-
tion, or any form of deformation, or narrowing of bronchi. 
The details of LT and BT techniques have been reported
elsewhere (4, 14). All LT was undertaken under general anes-
thesia. Both rigid and flexible bronchoscopes were used in
most cases. LT was given first to debulk tumors of the trachea
or main bronchi. BT in most cases was given one week after
LT in the CT group. The catheter was advanced using a nasal
approach if possible, under direct vision, and placed either
beyond or adjacent to the obstructing mass. The bronchoscope
was then removed over the catheter and a dummy source with
radio-opaque marking at 1 cm intervals was inserted through
the treatment catheter. The treatment was carried out using
an HDR remote afterloading system (Micro-Selectron; Nucle-
tron Oldelft Corp; Veenendaal, Netherlands) with a high ac-
tivity source. Both the chest physician and radiotherapist de-
termined the target volume, which included 1 to 2 cm securi-
ty margins on both sides of the main obstructed airway seg-
ment considering its location and length. After each treatment
session (lasting 5 to 10 min), the catheter was removed. A sec-
ond procedure was performed when required on a clinical
basis. The response to BT was assessed in 4 to 6 weeks.
Statistical Analysis
Data were analyzed using the Excel and SPSS statistical
software packages for Windows and expressed as percentages
or means±standard deviation (SD). Statistical significance was
evaluated by Student t-test, paired t-test, bivariate correla-
tion, and multiple analysis of variances (one-way ANOVA).
For univariate analysis, survival rates were calculated using
the Kaplan-Meier method. The p values were based on the
log-rank test (15). A simultaneous assessment of the effects of
different prognostic factors was performed within a multiple
regression analysis using the Cox model (16). Statistical sig-
nificance was set at p<0.05. 
RESULTS
Ninety-four patients were enrolled. Of these patients, data
from 14 were not included in the analysis (stent treatment
in 6, insufficient information in 6, and benign tumor in 2).
Eighty patients were included in this study, consisting of 56
men and 24 women. Sixty-seven had a primary lung cancer
and 13 had a metastatic lung cancer. The predominant histo-
logical type in the biopsies obtained was squamous cell cancer
(54%), followed by adenocarcinoma (14%), and 4 cases of
small cell lung cancer were included (5%). Patients’ charac-
teristics are shown in Table 1. Twenty-two subjects were treat-
ed with LT, 37 with BT, and 21 with CT. Groups were com-
parable with respects to age, white blood cell count, hemo-
globin, platelet count, calcium, alkaline phosphatase, alanine
aspartate, bronchoscopic findings, and stage, but the serum
albumin level of the CT group was significantly higher than
those in the other two groups (p=0.028, one-way ANOVA).
Seventy-five patients (94%) had tumors of advanced stage or
recurrent tumor. Five patients with operable stage in whom
surgery was contraindicated due to poor lung function were
included. Prevalence of squamous cell carcinoma significantly
increased with age (Pearson’ s correlation coefficient, 0.371;
p=0.001). Up to 82.9% of the patients had undergone prior
treatment for cancer; 52.6% had received a single modality
of treatment, and 30.3% had received two or more. The most
common previous treatment modality was EBRT (85.7%).
The primary cancer of metastatic lung cancer included renal
cell carcinoma (3 cases), esophageal cancer (2 cases), and one
each case of adrenocortical tumor, cholangiocarcinoma, colon
cancer, endometrial carcinoma, laryngeal tumor, malignant
fibrous histiocytoma, malignant melanoma, and ovarian can-
cer. Seventy-four patients (92%) had died, and six patients
were lost to follow-up (8%) at the time of the retrospective
study. 
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Fifty-three patients (91%) received a single session of BT, four
patients did two sessions, and only one patient did 3 sessions.
The mean dose received by the BT group was 12.3±3.8 Gy,
and that by the CT group was 12.7±4.5 Gy (p=0.719).
Table 2 lists the technical details of the BT. The mean length
of tissue treated, 5.08 cm, was accounted for by the 1 to 2 cm
margins of security on both side of the tumor site. Up to 86.5%
of patients experienced relief from their symptoms, subjec-
tively. The symptomatic response rate of the CT group was
higher than those of the other groups, but the difference was
statistically not significant (Table 3). 
The estimated overall median survival time was 138 days
(95% CI, 100-175 days) with actuarial 1-yr survival rate of
No. of patients  80  22 37 21
Age (yr)  64.7±12 65.6±12.8 65.3±11.4 62.4±12.6
Gender (male/female) 56/24  14/8 30/7 16/5
Diagnosis
Primary lung cancer 67 17 34 16
Metastatic lung cancer 13 5 3 5
Pathology
Squamous cell ca.  42 11 18  13
Adeno/Large cell ca.  14 4 6 4
NSCLC non-specified   9 4 5 0
Small cell ca.   4 0 3  1
Others 9 3 3 3
Location
Tracheal invasion 17 6 6 5
Major bronchi 49 15 20 14
Lobar bronchus 11 1 9 1
Bronchoscopic finding* 
EN type 39 12 19 8
EP type  24 10 3 7
EC typ 18 0  12 6
Stage
I-IIIa 5 3 0 2
IIIb 35 6 20 9
IV 20 10 6 4
Recurrent tumor 18 3 9 6
Laboratory finding
�
Hb 12.5±1.9 12.2±1.2 12.4±2.0 12.9±2.2
Albumin (g/L)
� 36.4±5.3 34.8±1.4 35.8±4.5 39±4.4
Calcium (mmol/L) 2.41±0.14 2.39±0.15 2.43±0.16 2.40±0.12
*p=0.028 among groups (one-way ANOVA).
� All values are expressed as mean±SD. 
� p=0.079 among groups (one-way ANOVA).
ca, carcinoma; LT, laser therapy; BT, brachytherapy; CT, combined
treatment; EN, endobronchial nodular and infiltrative; EP, endo-
bronchial polypoid; EC, extraluminal with compression.
Total  LT group BT group CT group
Table 1. Patient characteristics by treatment modality
Active source (cGy/m2/hr) 3,366.2 1,650 9,325
Total dose (Gy) 12.5 5 22.5
Time (sec) 364.5 145 848
Number of catheter 1.05 1 2
Active length (cm) 5.08 4 8
Frequency 1.11 1 3
Mean Minimum Maximum 
Table 2. Results of technical factors in brachytherapy (n=54) 
Yes 45 (86.5) 15 (83.3)  13 (81.3) 17 (94.4)
No 7 (13.5) 3 (16.7) 3 (18.8) 1 (5.6)
*Assessment of response in brachytherapy group was done 4-6 weeks
after treatment. 
LT, laser therapy; BT, brachytherapy; CT, combined treatment.
Total (%)  LT  BT CT
Table 3. Symptomatic response after treatment 
Stage 
I-IIIa   5 494 245-743 0.0061*, 0.0017
�
IIIb-IV 55 115  78-152
Recurrent disease 18 174 105-242
Treatment modality
LT group 22 111 24-198
BT group 37 115 77-153 
CT group 21 264 168-359 0.1411
� , 0.0078
�
Bronchoscopic finding
EN type  39 138 94-182
EP type   20 215 42-380 0.0757
‖, 0.0023
¶
EC type 18 115 48-182
Brachytherapy dose 
≥15 Gy at 1 cm 27 199 130-268 0.0077
< 15 Gy at 1 cm 27 98 57-139
Hemoglobin
≥12.5 g/dL 42 211 131-291 0.001
< 12.5 g/dL 37 98 75-121
Serum albumin level
≥37 g/L 40 205 77-337 0.0046
< 37 g/L 34 66 0-133
Symptomatic response
Yes 47 181 95-226 0.0147
No 7 104 1.4-206
Pathology
Squamous cell carcinoma 42 138 101-175 0.1041
Other pathologic types 36 98 75-120 
Diagnosis
Primary lung cancer 67 126 96-155
Metastatic lung cancer 13 269 126-412 0.135
*Stage I-IIIa vs IIIb-IV (log-rank test).
� Stage I-IIIa vs recurrent disease (log-rank test).
� LT vs CT (log-rank test).
�BT vs CT (log-rank test).
‖EN type vs EP type (log-rank test).
¶EP type vs EC type (log-rank test).
MST, median survival time; CI, confidence interval; LT, laser therapy;
BT, brachytherapy; CT, combined treatment; EN, endobronchial nodu-
lar and infiltrative; EP, endobronchial polypoid; EC, extraluminal with
compression 
No. MST  95% CIs   p value
(days) (days)
Table 4. Univariate survival estimates for patients from time of
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12.3%. Table 4 gives the detailed results of univariate analysis.
The median survival time was 264 days in the CT group,
while the LT and BT groups had lower median survival times
of 111 days and 115 days, respectively (p= 0.1411 for CT vs
LT and p=0.0078 for CT vs BT). The median survival in the
CT group is 2.3 times longer than those in the other groups,
but there was no statistical significance between LT and CT
group. The survival profile of the Kaplan-Meier estimate by
treatment modality is shown in Fig. 1. Analyses of survival
on the bronchoscopic findings revealed that the median sur-
vival time for the EP type was longer than those for the EN
and EC types, but a statistical significance was only between
EP and EC type (p=0.0023; survival curves shown in Fig. 2).
The following factors were associated with a better progno-
sis: hemoglobin ≥12.5 g/dL (p=0.001), dose of BT ≥15
Gy at 1 cm (p=0.0041, Fig. 3), serum albumin level ≥37
g/L (p=0.0046), and presence of a symptomatic response (p=
0.0147). White blood cell count, platelet count, alkaline
phosphatase, and aspartate transaminase were not associated
with survival outcome. Likewise, squamous cell carcinoma
histology, primary vs metastatic lung cancer, gender, presence
of tracheal involvement, age ≥65 yr-old, and previous EBRT
were not implicated in the survival. According to the results
of this univariate analysis, hemoglobin, albumin, dose of BT,
bronchoscopic findings, and treatment modality were the
covariates selected for potential inclusion in a multivariate
Cox regression model. The model selected included albumin
(p=0.0039), dose of BT (p=0.005), CT modality (p=0.05),
and bronchoscopic findings (p=0.02). The full model is pre-
sented in Table 5. 
There was no procedure-related death. The complication
rates were similar with 8 cases in 53 sessions (15.1%) in LT,
and 9 cases in 62 sessions (14.8%) of BT. Fever occurred in
1 case after LT and in 4 cases after BT. Four cases of minor
Albumin -0.072 0.04 0.931 (0.870-0.966)  0.039
Brachytherapy dose -0.113 0.04 0.888 (0.818-0.965) 0.005
CT -0.764 0.39 0.466 (0.217-0.999) 0.05
Bronchoscopic finding 0.02
EP vs EN -0.77 0.52 0.463 (0.166-1.289) 0.14
EP vs EC -1.009 0.37 0.365 (0.178-0.746) 0.006
EC vs EN  0.238   0.51  1.269 (0.471-4.418) 0.037
EN, endobronchial nodular and infiltrative; EP, endobronchial polypoid; 
EC, extraluminal with compression 
Variable Coefficient  SE HR (95% CI)  p value 
Table 5. Cox multivariate regression model
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Fig. 1. Survival estimates by treatment modality in all patients
with malignant tumors. 
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Fig. 3. Survival estimates by radiation dose of brachytherapy.
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Fig. 2. Survival estimates according to bronchoscopic finding.
EP, endobronchial polypoid type; EN, endobronchial nodular
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hemoptysis (less than 100 mL) was encountered in 5 cases,
however, none required specific treatment or admission to hos-
pital. Respiratory failure occurred in 2 cases after LT and 4
cases after BT, and responded well to supportive care (Table 6). 
DISCUSSION
EBRT often provides excellent local control and is the main-
stay of palliative therapy for bronchogenic cancer, however
local recurrence and extension is common (17, 18). These
patients may be candidates for LT and BT. There have been
few reports on the survival benefits of BT alone. Long-term
survival was observed rarely in selected cases whose tumor
size was limited (8, 9). There are several potential advantages
of BT used as an adjuvant to the LT in treating malignant
airway disease. It is well known that radiotherapy and che-
motherapy are poorly effective in the treatment of the endo-
bronchial component of tumors (19, 20). Laser techniques
should be limited to endobronchial exophytic tumor tissue
to a limit of 3-4 mm from the bronchial mucosa. BT reaches
tumor components in the bronchial mucosa and in the wall
up to a depth of 5-6 mm, depending on the dose given. BT
is thus complementary to laser techniques. Some studies have
suggested that patients who had undergone CT experienced
an improvement in their quality of life, less disease progres-
sion, and a reduction in the cost of treatment (14, 21). Only
a few studies have compared the survival benefit of CT with
that of single treatment modalities. Shea et al. (12), also in a
retrospective study, reported that the addition of BT might
increase the duration of patient survival compared to the pal-
liation with LT alone. The survival benefit they demonstrat-
ed was limited to subjects with squamous cell carcinoma, and
the results of our series do not support this finding. Their anal-
ysis did not include the BT alone group. Miller and Phillips (22)
suggested that CT improved local control of tumor compared
with either modality alone; however, due to the limited follow-
up in the CT group, possible correlation with survival could
not be revealed. 
Bronchoscopic finding is an important factor in predicting
treatment response. Taulelle et al. (23) reported that the size
of the extrinsic component of a tumor was related to treatment
results. They found a complete response rate of 62% in cases
with a limited extrinsic component as compared to 44% when
the extrinsic component was greater than 50% measured by
computed tomography. However, there has been no general
agreement on this point, since the presence of a predominant
extrinsic component is not considered to be a relative con-
traindication to the method by other authors, especially if
EBRT is used in association with BT (11, 22). Our study
showed a longer survival time in subjects with endobronchial
tumors, especially of the polypoid type. This is likely to be
because LT and BT are mostly effective in reducing intralu-
minal mass, but are less effective on extraluminal components.
The indications for BT in patients with extraluminal com-
pression type lung cancer must be carefully considered from
our results. Ofira et al. (24) indicated that patients presenting
with symptomatic endobronchial disease, regardless of whether
the disease was endobronchial or submucosal, showed objec-
tive improvement in endobronchial obstruction and radio-
graphic abnormalities following BT, but they could not de-
monstrate survival differences. The prognostic implication of
laboratory parameters has not been as studied extensively in
NSCLC. Low serum albumin level has been shown to have
poor prognostic implication in some studies, as well as low
hemoglobin level (25, 26). Our results also suggest that pre-
treatment normal hemoglobin and albumin levels are asso-
ciated with a better prognosis, however, since the size of our
study population is small, this observation needs further veri-
fication. 
Numerous reports have shown that BT is a very effective
technique, but no standardized fraction schedule has been
currently established. Langendijk et al. (27) reported that the
risk of massive pulmonary hemorrhage increased dramatically
when a fraction size of 15 Gy was used. However, Gollins et
al. (9) indicated that there was no overall difference in the
actuarial survival curves by 20 Gy compared with 15 Gy,
therefore a dose of 17.5 Gy at 1 cm from the central axis of the
source might represent an ideal compromise for single fraction
treatment. In one study using a single shot technique, 20 Gy
BT at 1cm distance from the source was associated with a
significantly higher rate of fatal hemorrhage than lower doses
(6). Our results revealed that the higher dose BT was associ-
ated with significant survival benefit, but we had to consider
the complication rate. In palliative care, a low complication
rate has an important effect on the quality of life. Accurate
calculation of the cumulative dose of irradiation is of great
importance to minimize side effects. Our study showed that
a dose of 15 Gy higher at 1 cm distance from the source was
associated with longer survival time without major compli-
cations. A dose of 15 Gy at 1 cm may be appropriate in the
palliative setting
The major complications directly attributable to the pro-
cedures such as fistulae, lung abscesses, massive hemorrhage,
and perforation were not seen in our study. Our fraction doses
were relatively low, which is one factor related to the absence
of major complications. In one study (28), five of 18 patients
Fever     1 4
Hemoptysis (< 100 mL) 3 1
Pneumothorax 1 0
Respiratory failure 2 4
Cardiac arrhythmia 1 0
Total (% of complication) 8 (15.1%) 9 (14.6%)
LT, Nd-YAG laser therapy; BT, brachytherapy.
LT (n=53) BT (n=62)
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died of massive hemorrhage. It is unclear if this was related
to disease progression or was a direct result of therapy. Hen-
nequin et al. (29) reported that hemoptysis is usually due to
disease progression, whereas radiation bronchitis is signifi-
cantly influenced by tumor location and technical factors such
as dose and volume. We may have incompletely ascertained
cases of massive hemorrhage and other late complications due
to the retrospective nature of our analysis, and incomplete
medical records held at the tertiary referral center. Patients
with locally advanced disease in whom the primary cause of
death is failure of other organ systems may not have lived long
enough to develop complications. Fatal hemorrhage peaked
at a mean of 10.5 months after the first treatment, suggesting
there may be a late reaction due to radiation overdose, which
needs to be taken into account (29). Some authors reported
the high risk of complications associated to the CT (10, 30),
but Cella et al. (14) reported there were neither morbidity
nor mortality related to the treatment. This is comparable
with our results. 
The limitation of our study is its retrospective nature. In this
setting, information such as performance status, the degree
of airway obstruction, radiological evaluation of the malignant
neoplasm, symptom index, details of follow-up bronchoscopy,
and late complications of treatment might not be routinely
reported, obtained, or not be available for evaluation, and
therefore not be included. Another limitation is the hetero-
geneity of the study subjects. There were many kinds of his-
tological type, different previous treatment histories, uneven
distribution of stage and bronchoscopic finding, and a wide
variation in patients’ characteristics. Furthermore, there was
a wide range of time intervals between the completions of
external irradiation or chemotherapy and the start of thera-
peutic bronchoscopic treatment, and this variable may effect
on the survival time. The observation that prior treatment
factors, histological type, sex, and tumor location did not
have a significant effect on patient’ s prognosis in our analy-
sis suggests that these factors are unlikely to be important
confounding factors.
We think the reasons for prolonged survival in the CT
group to be as follows. The first is a mechanical effect; as the
size of the mass is reduced after LT, the penetration of BT into
the residual tumor will be increased. Secondly, LT may have
promoted the tissue oxygenation and radiation damage by
the increased blood flow as a result of the local inflammation
relating laser irradiation and biologic effects such as increas-
ing blood flow within a tumor. Thirdly, differences in base-
line characteristics between the groups may have affected the
survival outcome. Uneven distribution of the endobronchial
type of tumor that is known to be more amenable to treat-
ment by LT/BT may be a relevant factor. 
Our study suggests that patients treated with BT in com-
bination with LT survive for longer time than those treated
with BT alone. However, a prospective randomized study
with longer follow-up is needed to determine the true extent
of this survival benefit. The continuing evolution in BT may
contribute to improvement of existing results. Our data sug-
gest that CT not only relieve symptoms, but also prolong
survival in selected patients. We believe that the combination
of laser resection with endobronchial radiotherapy is an effec-
tive technique for patients with endobronchial obstructing
tumors at an advanced stage, and a technique useful not only
for palliation of symptoms but also possibly associated with
survival benefit.
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